However, inhibition of TNF does not alter the state of insulin resistance in IBD patients (98, 99), and no differences in plasma insulin, glucose, and insulin resistance were noted in pediatric Crohn’s disease (CD) patients when comparing pre- and post infliximab (a chimeric anti-TNF antibody) treatment measurements (100). This evidence concerns the gene INS and Insulin resistance.